23andMe Acquires Lemonaid Health

October 22, 2021

23andMe agreed to acquire telemedicine and online pharmacy provider Lemonaid Health for a purchase price of $400 million (25% cash, 75% stock), in a deal expected to close by the end of 2021. The acquisition adds Lemonaid's telemedicine platform and prescription delivery services to 23andMe's consumer business; Lemonaid CEO Paul Johnson will become General Manager of 23andMe's consumer business.

Buyers
23andMe, Inc.
Targets
Lemonaid Health, Inc.
Location
California, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.